Literature DB >> 1679877

Septic shock: treatment.

J Cohen1, M P Glauser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1679877     DOI： 10.1016/0140-6736(91)91453-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

1.  More on pathogenesis and treatment of septic shock.

Authors:  D Fumarola; S Pece
Journal:  Eur J Epidemiol       Date:  1992-09       Impact factor: 8.082

Review 2.  Immunomodulators. Future prospects.

Authors:  B C Takx-Köhlen
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

3.  Binding of uridine 5'-diphosphate in the "basic patch" of the zinc deacetylase LpxC and implications for substrate binding.

Authors:  Heather A Gennadios; David W Christianson
Journal:  Biochemistry       Date:  2006-11-30       Impact factor: 3.162

Review 4.  Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal.

Authors:  J C Hurley
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

5.  Genome-wide expression profiling and mutagenesis studies reveal that lipopolysaccharide responsiveness appears to be absolutely dependent on TLR4 and MD-2 expression and is dependent upon intermolecular ionic interactions.

Authors:  Jianmin Meng; Mei Gong; Harry Björkbacka; Douglas T Golenbock
Journal:  J Immunol       Date:  2011-08-24       Impact factor: 5.422

Review 6.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

7.  Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo.

Authors:  C Szabó; C Thiemermann; C C Wu; M Perretti; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

8.  Characterization of specific binding of a human immunoglobulin M monoclonal antibody to lipopolysaccharide and its lipid A domain.

Authors:  Y Fujihara; M G Lei; D C Morrison
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

Review 9.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

10.  Role of tumour necrosis factor and reactive oxygen intermediates in lipopolysaccharide-induced pulmonary oedema and lethality.

Authors:  S Gatti; R Faggioni; B Echtenacher; P Ghezzi
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.